First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial - Scorecard - MDSpire

First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial

  • By

  • Peter Schmid

  • Seock-Ah Im

  • Zbigniew Nowecki

  • Piotr J. Wysocki

  • Jacek Jassem

  • Kyung Hae Jung

  • Simon Lord

  • Jon Armstrong

  • Ross Stewart

  • Petra Vuković

  • Neelima Denduluri

  • Yeon Hee Park

  • June 8, 2026

  • 0 min

Share

Clinical Scorecard: Evaluation of durvalumab in conjunction with trastuzumab deruxtecan for women with locally advanced unresectable or metastatic hormone-receptor-negative HER2-low breast cancer: A multicenter, open-label phase 1b/2 BEGONIA trial

At a Glance

CategoryDetail
Condition
Key MechanismsCombination of durvalumab and trastuzumab deruxtecan
Target Population
Care SettingMulticenter clinical trial

Key Highlights

    Guideline-Based Recommendations

    Diagnosis

      Management

        Monitoring & Follow-up

          Risks

            Patient & Prescribing Data

            58 participants with HR-negative, HER2-low breast cancer

            Median treatment duration was 11 months for durvalumab and 10 months for T-DXd.

            Clinical Best Practices

              Related Resources & Content

              Original Source(s)

              First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial

              • by Peter Schmid, Seock-Ah Im, Zbigniew Nowecki, Piotr J. Wysocki, Jacek Jassem, Kyung Hae Jung, Simon Lord, Jon Armstrong, Ross Stewart, Petra Vuković, Neelima Denduluri, Yeon Hee Park

              • June 8, 2026

              Related Content

              Lymphocyte CD4/CD8 ratio predicts early immune-related toxicity in lung cancer patients treated with immune checkpoint inhibitors: a single-center retrospective study

              A multi-task deep learning framework for simultaneous prediction of microsatellite instability and tumor mutational burden in gastric cancer from histopathological images

              Digital Twins as catalysts for Whole Person Health Mind Body Medicine in Integrative Oncology